IMRX logo

Immuneering Corporation

IMRX
Healthcare|Biotechnology|US
$3.68
+0.31 (+9.20%)
DCF Value
$2.80
Tangible Book / Share
$2.50
Cash / Share
$2.25
Next Earnings Report
Mar 5, 2027
EPS est. -$0.40
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (2)

Jun 2027
Est. completion
P1P2Advanced Solid Tumor
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320n=209
Jun 2028
Est. completion
P3Pancreatic Cancer
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152n=570

Recent Press Releases

Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
Nov 6, 2026 · GlobeNewsWire
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 4, 2026 · GlobeNewsWire
Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
Nov 4, 2026 · GlobeNewsWire
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
Oct 29, 2026 · GlobeNewsWire
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Oct 26, 2026 · GlobeNewsWire
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Oct 2, 2026 · GlobeNewsWire
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer
Sep 28, 2026 · GlobeNewsWire
Immuneering to Present at the ESMO Congress 2026
Sep 24, 2026 · GlobeNewsWire
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival
Sep 10, 2026 · GlobeNewsWire
Immuneering to Participate in Upcoming Investor Conferences
Sep 3, 2026 · GlobeNewsWire

SEC Filings (55)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 202610-QQuarterly reportDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Aug 5, 202610-QQuarterly reportDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Jul 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 15, 20268-KMaterial eventDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
Jun 1, 20268-KMaterial eventDocumentIndex
May 15, 202610-QQuarterly reportDocumentIndex
May 15, 20268-KMaterial eventDocumentIndex
Apr 20, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 20, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 6, 202610-KAnnual reportDocumentIndex
Mar 6, 20268-KMaterial eventDocumentIndex
Jan 22, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 7, 20268-KMaterial eventDocumentIndex
Nov 12, 202510-QQuarterly reportDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex
Oct 21, 2025SC 13GPassive 5%+ stakeDocumentIndex
Oct 7, 2025SC 13GPassive 5%+ stakeDocumentIndex
Oct 3, 2025SC 13GPassive 5%+ stakeDocumentIndex
Sep 25, 2025424B5Offering prospectusDocumentIndex
Sep 25, 20258-KMaterial eventDocumentIndex
Sep 25, 2025FWPDocumentIndex
Sep 24, 2025FWPDocumentIndex
Sep 24, 2025424B5Offering prospectusDocumentIndex
Sep 24, 20258-KMaterial eventDocumentIndex
Sep 9, 2025DDocumentIndex
Sep 8, 2025EFFECTDocumentIndex
Sep 8, 2025424B3Offering prospectusDocumentIndex
Sep 3, 2025S-3Shelf registrationDocumentIndex
Aug 25, 20258-KMaterial eventDocumentIndex
Aug 20, 2025EFFECTDocumentIndex
Aug 13, 2025S-3Shelf registrationDocumentIndex
Aug 13, 202510-QQuarterly reportDocumentIndex
Aug 13, 20258-KMaterial eventDocumentIndex
Jun 23, 2025424B5Offering prospectusDocumentIndex
Jun 17, 20258-KMaterial eventDocumentIndex
Jun 16, 20258-KMaterial eventDocumentIndex